OTTAWA, July 8
/PRNewswire-FirstCall/ - MDS Nordion, a leading provider of
products and services to the global health science market, today
announced it has signed a new contract with its primary customer,
Lantheus Medical Imaging, Inc. for the supply of Molybdenum-99
(Mo-99).
Mo-99, and, more specifically the derivative medial isotope
Technetium-99m, is utilized in approximately 80 percent of nuclear
medical procedures worldwide. These noninvasive procedures are
essential for accurately diagnosing and treating patients with
conditions such as heart disease, cancer and neurological
conditions.
"The continuous supply of medical isotopes to meet the needs of
the global medical community and the patients it serves has always
been an important priority for Nordion. This contract with Lantheus
further enables us to maintain that commitment," said Steve West, Chief Executive Officer, MDS Inc.
"Our depth of expertise in the industry, world-class logistical
team and proven capability in the production of medical isotopes,
provides Lantheus with a solid supply chain."
Under the terms of the new agreement MDS Nordion will supply
Mo-99 on a weekly basis to Lantheus Medical Imaging, Inc. This
contract is in place until July 31,
2011 and will commence once Atomic Energy of Canada
Limited's (AECL) National Research Universal (NRU) reactor has
returned to service which is anticipated to be the end of July,
2010.
"Lantheus and MDS Nordion have a long history of working
together and this contract further demonstrates our commitment to
provide medical isotopes to the global nuclear medicine community,"
said Don Kiepert, President and
Chief Executive Officer, Lantheus Medical Imaging, Inc. "MDS
Nordion provides the capacity and scalability Lantheus requires so
that doctors and their patients receive critical diagnostic scans
and treatments when they need them."
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global health science
company that provides market-leading products and services used for
the prevention, diagnosis and treatment of disease. We are a
leading provider of innovative technologies for use in medical
imaging and radiotherapeutics, and sterilization technologies
benefiting the lives of millions of people in more than 65
countries around the world. Our products and services are used
daily by pharmaceutical and biotechnology companies, medical-device
manufacturers, hospitals, clinics and research laboratories. MDS
has more than 700 highly skilled people in five locations. Find out
more at www.mdsnordion.com.
SOURCE MDS Inc.